These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33522314)

  • 1. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period.
    Pancholy M; Storey PP; Levin HJ; Obeid A; Patel SN; Kuley B; Hsu J; Spirn MJ; Fineman M; Klufas MA; Gupta O; Ho AC; Garg SJ
    Curr Eye Res; 2021 Sep; 46(9):1370-1377. PubMed ID: 33522314
    [No Abstract]   [Full Text] [Related]  

  • 2. COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
    Bavinger JC; Yu Y; VanderBeek BL
    Retina; 2019 Oct; 39(10):2004-2011. PubMed ID: 30312260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
    Storey PP; Tauqeer Z; Yonekawa Y; Todorich B; Wolfe JD; Shah SP; Shah AR; Koto T; Abbey AM; Morizane Y; Sharma P; Wood EH; Morizane-Hosokawa M; Pendri P; Pancholy M; Harkey S; Jeng-Miller KW; Obeid A; Borkar DS; Chen E; Williams P; Okada AA; Inoue M; Shiraga F; Hirakata A; Shah CP; Prenner J; Garg S;
    Am J Ophthalmol; 2019 Mar; 199():200-208. PubMed ID: 30552891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration.
    Daien V; Nguyen V; Essex RW; Morlet N; Barthelmes D; Gillies MC;
    Ophthalmology; 2018 Jan; 125(1):66-74. PubMed ID: 28801117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endophthalmitis after Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors: Management and Visual Outcomes.
    Xu K; Chin EK; Bennett SR; Williams DF; Ryan EH; Dev S; Mittra RA; Quiram PA; Davies JB; Parke DW; Johnson JB; Cantrill HL; Almeida DRP
    Ophthalmology; 2018 Aug; 125(8):1279-1286. PubMed ID: 29477689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
    Freiberg FJ; Brynskov T; Munk MR; Sørensen TL; Wolf S; Wirth MA; Becker M; Michels S
    Retina; 2017 Dec; 37(12):2341-2346. PubMed ID: 28099318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Endophthalmitis after Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength.
    Stem MS; Rao P; Lee IJ; Woodward MA; Faia LJ; Wolfe JD; Capone A; Covert D; Dass AB; Drenser KA; Garretson BR; Hassan TS; Margherio A; Oh KT; Raephaelian PV; Randhawa S; Sneed S; Trese MT; Yedavally S; Williams GA; Ruby AJ
    Ophthalmol Retina; 2019 Jan; 3(1):3-7. PubMed ID: 30929813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi Arabia.
    Al-Rashaed S; Alsulaiman SM; Alrushood AA; Almasaud J; Arevalo JF
    Middle East Afr J Ophthalmol; 2016; 23(1):60-3. PubMed ID: 26957840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilateral endophthalmitis following bilateral same-day anti-VEGF injections.
    Sepetis AE; Clarke B; Gupta B
    Acta Ophthalmol; 2021 Feb; 99(1):e131-e133. PubMed ID: 32533656
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influence of Universal Face Mask Use on Endophthalmitis Risk after Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    ; Patel SN; Tang PH; Storey PP; Wolfe JD; Fein J; Shah SP; Chen E; Abbey A; Ferrone PJ; Shah CP; Liang MC; Stem MS; Ali Khan M; Yonekawa Y; Garg SJ
    Ophthalmology; 2021 Nov; 128(11):1620-1626. PubMed ID: 34019955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center.
    Gonzalez-Gonzalez LA; Knickelbein JE; Doft BH; Balasubramani GK; Wisniewski S
    Int Ophthalmol; 2023 Mar; 43(3):867-876. PubMed ID: 36103102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis.
    Torres-Costa S; Ramos D; Brandão E; Carneiro Â; Rosas V; Rocha-Sousa A; Falcão-Reis F; Falcão M
    Eur J Ophthalmol; 2021 Mar; 31(2):600-606. PubMed ID: 32019339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of compounded bevacizumab with postinjection endophthalmitis.
    VanderBeek BL; Bonaffini SG; Ma L
    JAMA Ophthalmol; 2015 Oct; 133(10):1159-64. PubMed ID: 26270251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
    Xu Y; Tan CS
    Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Management Based on Vitreous Culture in Endophthalmitis After Intravitreal Anti-vascular Endothelial Growth Factor Injection.
    Patel SN; Storey PP; Pancholy M; Obeid A; Wibbelsman TD; Levin H; Hsu J; Garg SJ; Dunn JP; Vander JF
    Am J Ophthalmol; 2019 Nov; 207():224-231. PubMed ID: 31201794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
    Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
    Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
    Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.
    Inman ZD; Anderson NG
    Retina; 2011 Apr; 31(4):669-72. PubMed ID: 21178659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.